The debate begins over the timeline for boosters

·2 min read

Conflicting statements from Pfizer and the Biden administration were just the beginning of what will likely be a contentious debate over if and when vaccinated Americans need another shot to protect them against the coronavirus.

Why it matters: Making decisions based on emerging science is difficult on a good day. But until global supply outpaces global demand for the vaccine, how to allocate doses will remain a life-or-death decision.

Get market news worthy of your time with Axios Markets. Subscribe for free.

Driving the news: Biden administration officials met with Pfizer yesterday afternoon to discuss whether new data suggests that some Americans may soon need a third shot.

  • Sources say officials agreed that they need to continue looking at the data.

  • “For those who are at risk, there may be a need for boosts…the real risk is, right now there are people who are not vaccinated," a person familiar with the discussion in that meeting said. “No one walked out of there and said boosters are needed imminently.”

  • "We appreciate the information they shared, and officials continue to engage in a science-based rigorous process to consider whether, when, or for whom a booster might be necessary," an HHS official said in a statement to reporters.

Between the lines: Not only is the science unclear, but there would also likely be a global uproar if Americans began receiving a third shot before most of the rest of the world received any.

  • Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, said yesterday that Pfizer and other vaccine makers should focus on increasing global access to first doses, not boosters, STAT reports.

  • On the other hand, some Americans — especially older ones or those with health conditions — could become increasingly nervous about the status of their protection, especially after reading warnings like Pfizer's.

State of play: Recent studies have shown that the existing vaccines work against the Delta variant, but may be less effective.

  • A study out of Israel, released by the government, found that the Pfizer vaccine is only 64% effective against Delta infections, although it remained more than 90% effective against severe disease.

  • It was this study that led Pfizer to announce it would seek authorization for a third shot, former FDA Commissioner and Pfizer board member Scott Gottlieb said this weekend.

  • But other studies have shown higher efficacy against Delta, particularly against symptomatic infections — just slightly less than against the original version of the virus.

What they're saying: Gottlieb said that people vaccinated early on in the U.S. vaccination effort — who tend to be older — would be the ones to need a boost soon, not those vaccinated more recently.

What we're watching: Politics, both domestic and international, could end up being just as prominent within the booster conversation as the science.

More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting